AstraZeneca (LSE:AZN) recently reported a 1.9% decline in its share price over the last week. This movement coincides with ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the DESTINY-Breast09 Phase 3 trial of Enhertu (5.4mg/kg) ...

Analysts at Leerink Partners said in a Monday note that DESTIN-Breast09’s findings “could support an approval” for Enhertu in ...

AstraZeneca/Daiichi's Enhertu plus Perjeta shows better progression-free survival vs standard care in first-line HER2+ ...

Most of his assets have either been attached or disposed of at significantly reduced value, primarily due to ongoing ...

AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line ...

Shivinder and his brother Malvinder Singh were once India’s most hallowed figures in the healthcare industry. Grandsons of ...

AstraZeneca (NASDAQ:AZN) said on Monday that the late-stage trial for Enhertu, in combination with pertuzumab, showed ...

The data could help the Enhertu regimen overtake a drug combination that’s been used as the initial treatment for ...

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the ...

Springtime in Washington, D.C., is synonymous with cherry blossom season, when the thousands of cherry blossom trees gifted ...

Most of his assets have either been attached or disposed of at significantly reduced value, primarily due to ongoing ...